Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC). This is an ASCO Meeting Abstract from the 2020 Gastrointestinal ...

Transarterial chemoembolization (TACE) remains a cornerstone therapy for intermediate-to-advanced hepatocellular carcinoma (HCC); however, the optimal embolic platform remains uncertain. This ...

A phase I/II study of photodynamic therapy (PDT) using HPPH for the treatment of Barrett's and precancerous lesions of the esophagus. A phase II clinical trial of MK-0646, an insulin-like growth ...

In this review we will discuss TACE, TAE and TOCE in detail. The TACE procedure consists of the injection of anticancer drugs mixed with or without lipiodol into the hepatic artery followed by the ...

Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer. Patients with unresectable hepatocellular ...

The safety profile of durvalumab plus TACE and bevacizumab in patients with hepatocellular carcinoma in the phase 3 EMERALD-1 study appears to consistent with previous findings. Patients with ...

Transarterial chemoembolization (TACE), a minimally invasive procedure for liver cancer, is an effective treatment strategy for patients with large, asymptomatic, or multifocal hepatocellular ...

Hepatocellular carcinoma, the most common form of primary liver cancer, sits at the center of one of the most algorithm-driven fields in oncology. The Barcelona Clinic Liver Cancer (BCLC) staging ...

A safe and tolerable treatment option of transarterial chemoembolization combined with lenvatinib plus sintilimab was given to patients with hepatocellular carcinoma. Transarterial chemoembolization ...

Please provide your email address to receive an email when new articles are posted on . Hepatocellular carcinoma, the sixth most common cancer, accounts for 90% of primary liver cancers worldwide. Its ...

The efficacy of transarterial techniques can be assessed in terms of imaging response (CT scan), biologic response (AFP), degree of tumor necrosis, patient survival or quality of life. The most ...